Invitation to the EBAC-accredited Satellite Symposium "Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes".
For more information, please visit the ESC website.
Educational objectives
The educational objectives of the symposium are to:
• Evaluate the barriers to long-term hyperkalemia management with RAASi therapy for heart failure patients with comorbidities to improve patient outcomes
• Analyze case studies, considering the latest evidence on novel potassium binders, to optimize their use for hyperkalemia management in high-risk cardiorenal patients receiving RAASi therapy
• Develop evidence-based multidisciplinary strategies to identify, prevent, and manage hyperkalemia in patients with cardiorenal disease, focusing on early intervention, long-term maintenance, and patient-centered care
Agenda
15:15– 15:30 Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy - Gianluigi Savarese, MD - cardiologist, Stockholm, Sweden
15:30 – 15:55 A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care - Aaron Wong, MD - cardiologist, Bridgend, Wales, United Kingdom and James Burton, MD - nephrologist, Leicester, United Kingdom
15:55 – 16:00 Summarizing multidisciplinary strategies: Where do we go from here? - Gianluigi Savarese, MD - cardiologist, Stockholm, Sweden
CME Accreditation
This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) with 45 minutes effective education time. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Funding
This symposium is supported by an unrestricted educational grant from AstraZeneca.
